🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Japan / NCT06948422
Active, not recruiting Phase 3

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

NCT06948422 · tracked via the Priya Life Science Japan tracker
Phase
Phase 3
Started
2025-04-30
Last updated
2026-05-29

Condition(s) studied

Hypertension

Investigational drug(s) / intervention(s)

Orforglipron →Placebo

Orforglipron: Administered orally.

Placebo: Administered orally.

Study summary

The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a framework to evaluate the safety and efficacy of orforglipron for the treatment of hypertension in participants with obesity or overweight.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Has systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg (if DBP criteria alone is met, SBP must be ≥130 mmHg) at screening (Visit 1). * Has SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg (if DBP criteria alone is met, SBP must be ≥130 mmHg) at week 0 (Visit 3). * Untreated for hypertension, or on stable antihypertensive medications ≥ 30 days prior to Visit 1. * Have a body mass index (BMI) ≥ 25 kg/m². Exclusion Criteria: * Has SBP ≥170 mmHg and/or DBP ≥110 mmHg at Visit 1 or at Visit 3. * Has known secondary causes of hypertension * Have heart failure with reduced ejection fraction (HFrEF) diagnosis * Have had any of the following conditions within 90 days prior to screening. * hospitalization for hypertension or for congestive heart failure * acute coronary syndrome or acute myocardial infarction, or * cerebrovascular accident (stroke). * Have type 1 diabetes (T1D) * Have acute or chronic hepatitis, including a history of autoimmune hepatitis

Primary outcome measure(s)

Trial sites (100)

FacilityCityRegionStatus
Elite Clinical Studies, LLC Phoenix Arizona
Valley Clinical Trials, Inc. Covina California
Valley Clinical Trials, Inc. Northridge California
Chase Medical Research, LLC Waterbury Connecticut
Excel Medical Clinical Trials Boca Raton Florida
Care Access - Brandon Brandon Florida
Northeast Research Institute - Downtown Office Jacksonville Florida
Care Access - St. Petersburg St. Petersburg Florida
East-West Medical Research Institute Honolulu Hawaii
Sinai Hospital Of Baltimore Baltimore Maryland
Ascension Saint Agnes Heart Care Baltimore Maryland
Lucida Clinical Trials New Bedford Massachusetts
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division Troy Michigan
StudyMetrix Research City of Saint Peters Missouri
Excel Clinical Research, LLC Las Vegas Nevada
Palm Research Center Sunset Las Vegas Nevada
Rochester Clinical Research, LLC Rochester New York
Remington-Davis, Inc Columbus Ohio
PriMED Clinical Research Dayton Ohio
Advanced Research Institute - Tigard Tigard Oregon
Care Access - Mauldin Mauldin South Carolina
Dallas Heart and Vascular Consultants, PA Duncanville Texas
Texas Institute of Cardiology, PA McKinney Texas
North Hills Family Medicine/North Hills Medical Research North Richland Hills Texas
Advanced Research Institute Ogden Utah
Carient Heart & Vascular - Manassas Manassas Virginia
Health Research of Hampton Roads, Inc. Newport News Virginia
National Clinical Research, Inc Richmond Virginia
Eastside Research Associates Redmond Washington
Instituto Médico Especializado (IME) Buenos Aires Argentina
CIPREC Buenos Aires Argentina
CIPREC Buenos Aires Argentina
CEMEDIC Buenos Aires Argentina
Instituto de Investigaciones Clínicas Córdoba Córdoba Argentina
Centro de Investigaciones Clínicas Baigorria Granadero Baigorria Argentina
INECO Neurociencias Oroño Rosario Argentina
Instituto Médico Fundación Grupo Colaborativo Rosario Investigación y Prevención Medica Rosario Argentina
Santa Maria de la Salud Centro Medico San Isidro Argentina
Beijing Pinggu District Hospital Beijing China
China-Japan Union Hospital Changchun China

+ 60 more sites — see the full list on the official registry below.

More Eli Lilly and Company trials in Japan

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06948422 on ClinicalTrials.gov ↗ ← All trials in Japan